2.
Clinicopathological characteristics of Ventana IHC ALK (D5F3)-positive patients (N=27)
| No. | Age (year) | Gender | Smoking history | ALK-IHC | ALK-FISH (%)* | Tumor content (%) | EGFRmutations | TTF-1-IHC | P63-IHC |
| ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; *, percentage of split signalsby FISH; EGFR, epidermal growth factor receptor; TTF-1, thyroid transcription factor-1; M, male; F, female; PY, pack-years; N, none; WT, wild-type. | |||||||||
| P1 | 52 | M | 15PY | + | Indefinite | 10 | WT | + | – |
| P2 | 45 | F | N | + | + (30) | 40 | WT | + | – |
| P3 | 24 | F | N | + | + (36) | 60 | WT | + | – |
| P4 | 79 | M | N | + | + (54) | 50 | WT | + | – |
| P5 | 47 | M | N | + | Indefinite | <10 | WT | + | – |
| P6 | 35 | M | 5PY | + | + (40) | 50 | WT | + | – |
| P7 | 58 | M | 30PY | + | + (66) | 70 | WT | + | – |
| P8 | 82 | M | 30PY | + | + (60) | 70 | WT | + | – |
| P9 | 66 | F | N | + | –(12) | 90 | WT | + | + |
| P10 | 70 | M | 25PY | + | + (20) | 30 | WT | + | – |
| P11 | 70 | F | N | + | + (50) | 30 | WT | + | – |
| P12 | 62 | F | N | + | + (30) | 50 | WT | + | – |
| P13 | 60 | F | N | + | + (52) | 40 | WT | + | – |
| P14 | 57 | F | N | + | + (36) | 70 | WT | + | – |
| P15 | 54 | F | N | + | + (20) | 30 | WT | + | – |
| P16 | 52 | M | N | + | + (30) | 30 | WT | + | – |
| P17 | 48 | F | N | + | + (60) | 80 | WT | + | – |
| P18 | 79 | M | 30PY | + | + (36) | 30 | WT | + | – |
| P19 | 44 | F | N | + | + (52) | 30 | WT | + | – |
| P20 | 45 | M | 5PY | + | –(14) | 80 | WT | + | – |
| P21 | 50 | M | N | + | + (40) | 50 | WT | + | + |
| P22 | 51 | F | N | + | + (40) | 20 | WT | + | – |
| P23 | 69 | M | 30PY | + | + (50) | 40 | WT | + | – |
| P24 | 21 | F | N | + | + (30) | 30 | WT | + | – |
| P25 | 71 | F | N | + | + (56) | 60 | WT | + | – |
| P26 | 48 | F | N | + | + (60) | 40 | WT | + | – |
| P27 | 31 | F | N | + | + (62) | 50 | WT | + | – |